Treatment Satisfaction With Omnipod DASH in Adults With Type 1 Diabetes: A Nonblinded 1:1 Randomized Controlled Trial

Area of Science:

• Endocrinology
• Medical Devices
• Diabetes Technology

Background:

• The Omnipod DASH Insulin Management System offers a tubeless alternative to conventional insulin pump therapy (IPT), addressing physical inconveniences.
• Type 1 diabetes management often involves multiple daily injections (MDIs) or tubed IPT.

Purpose of the Study:

• To compare treatment satisfaction between the Omnipod DASH System and usual care (MDIs or tubed IPT) in adults with type 1 diabetes using self-monitoring blood glucose (SMBG).

Main Methods:

• A 12-week, nonblinded, randomized trial assigned adults with type 1 diabetes (on MDI or IPT) to either the Omnipod DASH System or usual care.
• The primary outcome was treatment satisfaction measured by the change in the Diabetes Technology Questionnaire "current" (ΔDTQ-current) score at 12 weeks.
• Secondary outcomes included participant-reported outcomes (PROs) on quality of life, treatment burden, and glycemic control over 24 weeks.

Main Results:

• The Omnipod DASH group showed significantly greater improvements in treatment satisfaction (ΔDTQ-current: 16.4 vs 0.0; P < .001) compared to the Usual Care group at 12 weeks.
• Significant improvements were also observed in other PROs and glycated hemoglobin A1c (HbA1c) levels.
• While time in range did not differ at 12 weeks, it significantly improved by 24 weeks in the Omnipod DASH group (5.6%; P = .016).

Conclusions:

• The Omnipod DASH System enhances treatment satisfaction in adults with type 1 diabetes using SMBG, with sustained benefits at 24 weeks.
• The system did not compromise sleep quality or increase fear of hypoglycemia.
• Improvements in glycemic control, including HbA1c and time in range, were observed with the Omnipod DASH System.